Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Stijn Jh WaaijerDanique GiesenTakahiro IshiguroYuji SanoNaofumi SugayaCarolina P SchröderElisabeth Ge de VriesMarjolijn N Lub-de HoogePublished in: Journal for immunotherapy of cancer (2021)
[89Zr]Zr-N-suc-Df-ERY974 can potentially be used to study ERY974 biodistribution in patients to support drug development.